Inhibrx Biosciences, Inc.
INBXHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. With a market capitalization of $1.46B, it sits in small-cap territory. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Market Cap
$1.46B
Beta
3.89
P/E (TTM)
—
P/E (Fwd)
-35.59
EPS (TTM)
$-8.39
EPS (Fwd)
$-2.79
ROE
-354.7%
ROA
-36.1%
Cash
$161.7M
Total Debt
$180.9M
Free CF
-$89.1M
52W Change
633.9%
Annual Financials
Cash vs Debt
The company holds $161.7M in cash, though total debt stands at $180.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$89.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -354.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $1.3M (2022) to $1.3M (2025).
Inhibrx Biosciences, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing INBX.